Taking Cancer Prevention on the Road

Page 10

Drug Developed at Ohio State Has Patient Going 180 Miles Strong Page 8
How Philanthropy Became a Family Affair Page 12
A Journey Through Young Adult Cancer Page 16
There’s something new in the community that we encourage everyone to watch for. It’s called The James Mobile Education Kitchen, a vividly colorful kitchen that wheels around the region with information about nutritional health and wellness, including foods that reduce cancer risk.

This venerable vehicle is also a rolling monument to the power of philanthropy. Its purchase was enabled by a $500,000 gift from Celebration for Life, an annual dinner event founded by Judy and Steve Tuckerman to benefit The James Fund for Life, which was established in 2002 by Abigail and Les Wexner to raise money for technologies and equipment that enhance cancer research and patient care at Ohio State.

The Mobile Education Kitchen is our cover story in this issue of impactCancer, but it’s not the only story herein with a focus on philanthropy. Another spotlights the Smullen family of Worthington—a father and three children who established the Smullen Family Fund for Breast Cancer Research. This fund has generated more than $50,000 through fundraisers the family holds each year in honor of Cindy Smullen, a wife and mother whose spirit and generosity live on in the husband and children she left behind after a nearly 10-year battle with breast cancer.

In addition, this issue will help you get to know the two of us a little better through a pair of personal profiles and from coverage of a “Meet the Cancer Program Leaders” forum on May 2 that also featured Peter Shields, MD, deputy director of Ohio State’s Comprehensive Cancer Center, and David Cohn, MD, chief medical officer at the James Cancer Hospital and Solove Research Institute. Each of us spoke at the forum about exciting projects ahead that will need community support. A story in the digital version of impactCancer contains a link for viewing the full forum.

Many other intriguing stories appear in this issue. We hope you will enjoy them all.

R. E. Pollock, MD, PhD
Director, The Ohio State University
Comprehensive Cancer Center

William Farrar, MD
Interim CEO, James Cancer Hospital
and Solove Research Institute
Experience, Expertise, Excitement: Meet Our Cancer Center Director, Dr. Raphael Pollock

‘I Love The James’: Get to Know Dr. William Farrar, Our Interim CEO

Drug Developed at Ohio State Has Patient Going 180 Miles Strong

Where Flavor and Cancer Prevention Go Hand In Hand: Cutting the Ribbon on the Mobile Education Kitchen

Beloved Wife and Mother Inspires Philanthropy From Family, Community

An Unknown Illness, an Uncertain Future, and Unbreakable Spirit: A Journey Through Young Adult Cancer

‘Celebration for Life’ Raises $1.23 Million

Top Pelotonia-Funded Areas of Impact

OSUCCC – James Leaders Extol Cancer Program’s Caring Culture

Single Upfront Genomic Test Improves Lynch Syndrome Detection Rates

‘Floating Buckeye Nation’ Sets Sail and New Fundraising Record

OSUCCC – James
Chief Communications Officer: Melissa Hall

Editor: Stacy Fronczak
Designer: Lori Zamitto
Creative Director: Kathleen Lilash
Contributing Writers: Alice Duncanson Steve Wartenberg
Contributing Photographers: Alan Geho Greg Miller Steve Runyon

impactCancer is published three times each year by the Development and Marketing departments of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

OSUCCC – James Office of Development
660 Ackerman Road
P.O. Box 183112
Columbus, Ohio 43218-3112
614-293-3752

Like us on Facebook cancer.osu.edu/Facebook
Follow us on Twitter cancer.osu.edu/Twitter
Subscribe to us on YouTube cancer.osu.edu/YouTube
Follow us on LinkedIn cancer.osu.edu/LinkedIn
Follow us on Pinterest cancer.osu.edu/Pinterest
Visit our website cancer.osu.edu
Experience, Expertise, Excitement:
Meet Our Cancer Center Director, Dr. Raphael Pollock

Months after Raphael Pollock, MD, PhD, moved into his new office, it is still filled with boxes he hasn’t had time to unpack. Text messages and emails arrive at a fast and furious pace, and by the time he finishes one meeting, he’s a few minutes late for the next.

Nevertheless, the calm, kind, confident and humble Pollock is thriving as director of The Ohio State University Comprehensive Cancer Center (OSUCCC). “This is what revs my engine,” he says. “I’m excited.”

Pollock has been treating cancer patients for 35 years as a surgeon specializing in soft tissue sarcomas while also breaking new ground as a research scientist. He most recently served as the primary investigator for one of the first large-scale research collaborations between multiple cancer centers funded by the National Cancer Institute (NCI).

“It’s ultimately all about caring for patients,” he says. “My new position provides a bigger platform to do that, and being part of this amazing team of committed caregivers and investigators is a remarkably positive experience.”

Pollock was recently diagnosed with cancer and says the experience has brought him even closer to his patients.

Patient Care: A Family Affair

Pollock grew up in Chicago, where his father, George Pollock, MD, PhD, was a prominent psychiatrist who inspired three of his five children to choose medicine as a career.

Raphael Pollock majored in history at Oberlin College, then attended Saint Louis University School of Medicine. “I saw how remarkable the surgeons were in taking care of their patients, and I fell in love with it,” Pollock says of his third-year medical school surgical rotation.

Fighting Cancer Becomes a Career

Pollock completed his surgical residency at the University of Chicago and Rush Medical School. Then a surgical oncology fellowship at MD Anderson Cancer Center in Houston connected him with a specialization in sarcomas, a type of cancer that develops in the bones and in soft tissues such
as muscles, nerves and blood vessels. His initial rotation as a fellow at MD Anderson was with the sarcoma medical oncology team—a life-changing moment that Pollock remembers well.

The team encountered a young patient with a sarcoma in his humerus (upper arm bone), which had fractured. When the attending physician asked the fellows for recommendations, Pollock said radical amputation had been the proper procedure in a similar case he’d seen less than a week before, while he was still a resident.

But instead of an amputation, the patient underwent chemotherapy, radiation and then surgery, which included the replacement of his shoulder joint. “By the end of the summer, he was playing tennis again,” Pollock says.

This jump-started Pollock’s career for specializing in soft tissue sarcoma—a rare disease that accounts for about 1 percent of all solid tumor diagnoses.

Leading the Way to Better Cancer Research Collaboration

Pollock’s research career also began during his surgical oncology fellowship at MD Anderson. “The NCI launched a new research training program in the early 1980s—the K08 Clinician-Investigator Award series,” Pollock says. “I was lucky enough to receive one of these early awards and chose to enroll in a PhD program in tumor immunology at the Graduate School of Biomedical Biological Sciences in Houston.”

He spent the next 10 years studying the impact of surgery on perioperative antitumor immunity mediated by natural killer (NK) cells, a subset of circulating lymphocytes within the immune system. However, it was difficult to show that NK cells had a role against soft tissue sarcomas, given the research methodologies available at that time.

“I was encouraged by several senior scientists at MD Anderson to begin examining the molecular drivers underlying sarcoma proliferation and metastasis, and this led to a new series of translational laboratory investigations focusing on molecularly oriented sarcoma research,” says Pollock. “This has been the focus of our laboratory ever since.”

Pollock came to Ohio State in 2013 after 31 years at MD Anderson, where he served as professor and head of surgery for 17 years. At Ohio State, Pollock has served in several leadership roles: vice chair for clinical affairs in the Department of Surgery; director of the Division of Surgical Oncology; director of the Sarcoma Research Laboratory; surgeon-in-chief for the OSUCCC – James and surgeon-in-chief for The Ohio State University Health System. He also holds the Klotz Family Chair in Cancer Research.

As director of the OSUCCC, Pollock will devote his efforts to “the critical task of supporting the entire research effort at one of the largest and best cancer centers,” he says. “The breadth, quality and collaborative interest of the research here is as strong as you’ll find anywhere.”

Doctor, Director, Researcher, Patient

Pollock himself has benefited from some of this research. In January 2017 he was diagnosed with chronic lymphocytic leukemia (CLL). John C. Byrd, MD, co-leader of the Leukemia Research Program at the OSUCCC, is one of the world’s leading experts on CLL. He and his research team played a large role in developing ibrutinib, an FDA-approved drug and a game-changing improvement for treating certain CLL patients.

“I’m very lucky to be in the right place,” says Pollock, who takes ibrutinib daily. “I am so grateful to John and his colleagues for their compassion and knowledge.”

Pollock is “cautiously optimistic” about his long-term prognosis.

“It has added a little spice to this whole proposition,” he says. “And because there’s some uncertainty, it has also added a sense of urgency. I’m even more determined to create opportunities for all the amazing people here that will hopefully translate into even better care for our patients.”

“It’s ultimately all about caring for patients. My new position provides a bigger platform to do that, and being part of this amazing team of committed caregivers and investigators is a remarkably positive experience.”

— Raphael Pollock, MD, PhD
There weren’t many options for women diagnosed with breast cancer in the 1970s. “When I was going through training, we would do a radical mastectomy 70 or 80 percent of the time,” says William Farrar, MD. “We’d remove all the breast tissue, the muscles of the chest wall and all the lymph nodes under the arm—that’s how breast cancer was treated for 80 years.”

The past few decades have seen numerous advances in treating breast cancer, thanks to pioneering physicians and leaders such as Farrar. He’s performed more than 10,000 breast cancer surgeries and helped develop new and less-invasive techniques. He’s also trained and mentored a generation of oncology surgeons who practice at hospitals around the country, participated in several clinical trials that have led to better chemotherapy and immunotherapy treatments and helped create one of the nation’s first multimodal breast cancer clinics.

And Farrar did all of this at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).

For these reasons, plus one more, it seems fitting that he recently was appointed the interim CEO of The James.

That one additional reason?

“Dr. James was my mentor,” Farrar says, adding that, as far back as the 1940s, Arthur G. James, MD (1912-2001), had a dream of creating a dedicated cancer hospital in Columbus to treat patients from central Ohio and beyond.

“Dr. James started his medical training before World War II, served in the war as a doctor, came back and eventually finished his (surgical) fellowship and came to Ohio State,” Farrar explains. “He was the only surgical oncologist in the entire state at first, and he went all over Ohio to operate—on every type of cancer. His manner with his patients was outstanding, and they just loved him. It was such a great honor to work with him.”

When Farrar came to Ohio State as a surgical resident in 1975, he eventually became James’ protégé and, like his mentor, performed surgeries on patients with a wide variety of cancers. The two eventually became partners in a surgical oncology practice based at Ohio State.

“That was the norm back then, to operate on all types of cancer, and it wasn’t until 1990, when The James opened, that we started to specialize,” Farrar says. Soon after his namesake hospital opened in July 1990, James retired from seeing patients but remained at the hospital in an emeritus role until 1996.

As Farrar began to specialize in breast cancer surgery and treatment, he and others at the OSUCCC – James realized there was a need for a separate facility to accommodate the growing number of breast cancer patients they were treating.

“We took all the disciplines that treated breast cancer—the surgeons, the medical oncologists, plastic surgery, radiation, imaging and pathology—and we put a clinic together,” he says of the facility that was located near Dublin, Ohio. It opened in 1997. “We were very successful, and our patients and our staff loved it, but we quickly outgrew the facility.”

This led to the Stefanie Spielman Comprehensive Breast Center, a state-of-the-art facility that opened in 2011 and took the multimodal concept to a new level. “When we moved, we were seeing 430 new patients a year, and this year we’ll go over 1,000,” Farrar says, adding that patients come from all over Ohio and outside the state to be treated at the Spielman Center. “I haven’t heard of, or seen, another breast cancer facility that has everything that we have here.”

As the number of breast cancer patients grew, so did the treatment options offered by Farrar and his colleagues at The James. There are more than a dozen new chemotherapy drugs for breast cancer patients, along with less-invasive surgeries—no longer are multiple lymph nodes removed—as well as immunotherapy treatments that show great promise. That innovation has helped lead to a dramatic improvement in outcomes for many breast cancer patients.
“Every aspect of breast cancer treatment has changed so radically in the past 30 or 40 years,” Farrar says. “This has been so rewarding for me, and now there’s so much more hope.”

One thing that hasn’t changed is the importance of the lessons passed down from Dr. James, which Farrar has since shared with scores of OSUCCC – James staff members.

“The number-one lesson I pass on from Dr. James is that the patient is number one. They’re going through a tough time, and you really have to take care of your patients and treat them like they’re a member of your own family,” Farrar says.

Over the years, some of Farrar’s many Ohio State leadership positions have included division chief of surgical oncology (1985-2012), director of medical affairs (1989-2011) and director of the Spielman Center (2011 to the present). He also holds the Dr. Arthur G. and Mildred C. James – Richard J. Solove Chair in Surgical Oncology. Farrar has authored more than 100 peer-reviewed publications and has been the principal investigator on several important grants and clinical trials.

Farrar, 69, was starting to think about cutting back his schedule when he was approached about serving as the interim CEO of The James. He and his wife, Kathryn, have four adult children and four grandchildren.

“This isn’t something I ever thought about doing,” Farrar says of his new role. “But I’ve been here my whole life. I love The James, and I am willing to do anything I can to continue to move our cancer program forward.”

OSUCCC – JAMES ONCE AGAIN ACHIEVES MAGNET® RECOGNITION

Countless hours of work and dedication over many months paid off in a big way for OSUCCC – James faculty and staff on March 15 when they learned that the hospital has, for the second time, achieved Magnet® recognition from the American Nurses Credentialing Center (ANCC). The news was delivered by Donna Havens, PhD, RN, FAAN, chair of the Commission on Magnet Recognition, in a phone call that was streamed at The James and five other cancer program sites where employees had gathered in eager anticipation.

The Magnet Recognition Program recognizes healthcare organizations for quality patient care, nursing excellence and innovations in professional nursing practice. The OSUCCC – James is among only 30 healthcare organizations in Ohio to have Magnet status, an honor that the hospital initially achieved in 2013. The renewed Magnet status will extend for four years.
At The James

Drug Developed at Ohio State Has Patient Going 180 Miles Strong

When Robert Bowen, now 68, of Huntington, W. Va., went for a colon cancer screening in February 2013, the last thing he expected was to receive a leukemia diagnosis.

Doctors wanted to start him on chemotherapy in short order. Bowen and his family, however, were concerned about the long-term effects of this treatment approach and asked for a second opinion. His local oncologist referred him to The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).

Testing at both the OSUCCC – James and the Cleveland Clinic suggested his cancer, chronic lymphocytic leukemia (CLL), was slow growing and may not require immediate treatment. The doctors suggested a watch-and-wait approach, with regular monitoring via bloodwork and imaging.

About 18 months later, however, Bowen’s lymph nodes began swelling throughout his body. Tests confirmed the disease had accelerated rapidly, and he could no longer delay treatment.

“I was really down in the dumps. I didn’t feel like I had any choice but to go on chemotherapy. I had a follow-up appointment at Ohio State. My wife and I decided to wait and check in with the team one more time before we made a choice about treatment,” he recalls.

That decision ended up being a game-changer, because he qualified for a clinical trial testing a new oral drug called acalabrutinib. The drug is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, a newer class of drugs shown to improve the survival of patients with CLL and mantle cell lymphoma (MCL). All preclinical research and the first phase I study of the drug were completed by a team of researchers led by John C. Byrd, MD, at the OSUCCC – James.

“I will never forget it, because Dr. Byrd said, ‘You know you are a candidate for our trial?’ It was so nonchalant, but it meant I had another option,” Bowen says. He started the trial a week later, in December 2014. Within a few days, his lymph nodes had visibly shrunk. Follow-up tests over the next year...
The OSUCCC – James is proud to join another great team by working with the Kay Yow Cancer Fund and NCAA Women’s Basketball to fight endometrial (uterine) cancer through a new $100,000 grant presented March 28 at the Women’s Final Four in Columbus. The Kay Yow Cancer Fund was founded in 2007 from the vision of Kay Yow, former North Carolina State University head women’s basketball coach. The fund’s focus is to end women’s cancers.

David Cohn, MD, chief medical officer of the James Cancer Hospital and Solove Research Institute, and director of the Division of Gynecologic Oncology, accepted the grant on behalf of his research colleagues in the division and at the OSUCCC – James, as well as at Nationwide Children’s Hospital (NCH).

Endometrial cancer (EC) is the most common gynecologic cancer in the developed world and the fourth most common cancer among women in the United States, with over 63,000 diagnoses expected in 2018. While most women with EC have a favorable prognosis following hysterectomy, some patients have a poor outcome. Identification of factors that predict poor outcome has been elusive, but with an expanded knowledge of the genetic basis of cancer, researchers have begun exploring molecular prognostic factors—the genetic signature of the cancer that may predict outcome.

The grant will enable the OSUCCC – James and NCH team to test the genetic signature of a large sampling of women with EC and correlate this signature with clinical outcome. Identifying the signature that predicts outcome will allow for a more refined approach to determining which women might benefit from additional therapy following hysterectomy to improve survival and quality of life.

**Cycling as a Mission**

Before his cancer diagnosis, Bowen enjoyed cycling as a casual pastime, but afterward it became much more to him. “My bicycle became a barometer for my health. I could feel myself getting stronger. Before my diagnosis, I enjoyed riding, but after, it became my mission,” he recalls.

In 2015, he participated in Pelotonia, an annual grassroots cycling event that raises money for cancer research at the OSUCCC – James, by joining the Pelotonia Team Buckeye-Hope Highway team and riding 100 miles in the event. He recalls standing at the starting line at 6 a.m., feeling awestruck and humbled by the number of people there to raise money for cancer research.

“I was randomly snapping pictures of the crowd and accidentally took a full-face photo of a specific man. Later, I ran into that same man coincidentally on the route, and we chatted for about an hour before parting ways,” he says.

It felt like more than a coincidence to Bowen the next year when the same man—Thomas Rogers, a five-year Pelotonia rider—rolled up next to him during Pelotonia 16. They decided to stay in touch and made plans to ride together in 2017.

“Tom joked that if we rode together, I had to do the whole thing. So that year I rode the 180,” Bowen says.

Bowen raised more than $3,000 in Pelotonia 17 and says he will continue to ride every year for as long as he is able.

To learn more about clinical trials at the OSUCCC – James, visit cancer.osu.edu/clinicaltrials. To learn more about Pelotonia, visit pelotonia.org.

**DR. COHN ACCEPTS GRANT FROM THE KAY YOW CANCER FUND**

The OSUCCC – James is proud to join another great team by working with the Kay Yow Cancer Fund and NCAA Women’s Basketball to fight endometrial (uterine) cancer through a new $100,000 grant presented March 28 at the Women’s Final Four in Columbus. The Kay Yow Cancer Fund was founded in 2007 from the vision of Kay Yow, former North Carolina State University head women’s basketball coach. The fund’s focus is to end women’s cancers.

David Cohn, MD, chief medical officer of the James Cancer Hospital and Solove Research Institute, and director of the Division of Gynecologic Oncology, accepted the grant on behalf of his research colleagues in the division and at the OSUCCC – James, as well as at Nationwide Children’s Hospital (NCH).

Endometrial cancer (EC) is the most common gynecologic cancer in the developed world and the fourth most common cancer among women in the United States, with over 63,000 diagnoses expected in 2018. While most women with EC have a favorable prognosis following hysterectomy, some patients have a poor outcome. Identification of factors that predict poor outcome has been elusive, but with an expanded knowledge of the genetic basis of cancer, researchers have begun exploring molecular prognostic factors—the genetic signature of the cancer that may predict outcome.

The grant will enable the OSUCCC – James and NCH team to test the genetic signature of a large sampling of women with EC and correlate this signature with clinical outcome. Identifying the signature that predicts outcome will allow for a more refined approach to determining which women might benefit from additional therapy following hysterectomy to improve survival and quality of life.

**Stephanie Glance, CEO, Kay Yow Cancer Fund, presents the grant award to Paul Goodfellow, PhD, and David Cohn, MD.**
Where Flavor and Cancer Prevention Go Hand in Hand:
Cutting the Ribbon on the Mobile Education Kitchen

The new Mobile Education Kitchen started its engine—and handed out tasty samples of freshly made quinoa granola—during a May 11 ribbon-cutting ceremony in front of the James Cancer Hospital and Solove Research Institute.

In attendance were Judy and Steve Tuckerman, founders of Celebration for Life, the annual signature event that benefits The James Fund for Life, established by Abigail and Les Wexner. Celebration for Life has raised $18.9 million since 2002 for technologies and equipment for cancer research and patient care at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).

Shown from left at the ribbon-cutting ceremony are chef David Brue; Judy and Steve Tuckerman; James Interim CEO William Farrar, MD; OSUCCC Director Raphael Pollock, MD, PhD; and chef Jim Warner.
A $500,000 gift from Celebration for Life enabled the purchase of the Mobile Education Kitchen, which educates the public about nutritional health and wellness. Speaking at the ribbon-cutting ceremony, James Interim CEO William Farrar, MD, noted the importance of focusing on nutrition as it relates to cancer prevention. “This includes directing specific attention to the American Institute for Cancer Research’s nutritional recommendations and demonstrating flavor-filled ways these foods can be prepared.”

It’s an exciting concept that the Tuckermans were eager to get behind. In her remarks during the ceremony, Judy described their enthusiasm for the mobile education concept. “When Steve and I learned of the idea to create a Mobile Education Kitchen to help educate patients and the community on healthy eating and cancer-fighting foods, we were sold,” she says. “We knew this was what we wanted the funds from last year’s Celebration for Life event to go toward.”

Sporting a brightly painted display of tantalizing fresh fruits and vegetables along its sides, the mobile kitchen will be hard to miss at events such as community festivals and other places where the public gathers. A team of chefs and dietitians, as well as Ohio State students completing dietetic internships, will offer cooking demonstrations, food samples and nutrition information.

It’s an important and timely mission, given the frequent breakthroughs in nutritional research and updates to dietary recommendations. As OSUCCC Director Raphael Pollock, MD, PhD, noted during the ribbon-cutting ceremony, Ohio State and the OSUCCC – James have a long history of leading research into cancer preventive foods. “For a number of years our cancer center has researched and published on the cancer-preventive properties of certain foods, such as black raspberries, tomatoes and soy,” he said. “The Mobile Education Kitchen will bring those findings directly to the public.”

Indeed, when it comes to cooking, health and taste do not have to be at odds with each other; ideally they complement one another.

“It’s one thing to tell people how they should eat for optimal health, but teaching them how to cook these foods in a tasty way that results in real diet changes that are sustainable is a very different thing,” says Jim Warner, program director of nutrition services at Ohio State Wexner Medical Center. “That is where change happens.”

This is the change the Tuckermans and Celebration for Life donors hope the mobile kitchen will help to trigger in central Ohio. “We’re incredibly grateful to the Tuckermans and all of those in the community who support Celebration for Life,” says Pollock. “These purchases are so important because they cover community needs that we could not address without philanthropy.”

**HARVESTING HEALTHY HABITS**

Vegetables, fruits and grains are chock-full of phytochemicals, which are naturally occurring chemicals in plants “that may prevent cancer from occurring or from spreading,” says Dena Champion, MS, RD, LD, an outpatient clinical oncology dietitian at the OSUCCC – James.

Phytochemicals stimulate the immune system, block substances that people eat, drink and breathe from becoming carcinogens, reduce inflammation that can lead to cancer, prevent DNA damage and slow the growth rate of cancer cells, according to the American Institute for Cancer Research.
Beloved Wife and Mother Inspires Philanthropy From Family, Community

Cindy Smullen had an infectious laugh that filled the Worthington home she shared with husband Greg and children Jake, 20, Abby, 17, and Emme, 13, with warmth. She was a stay-at-home mother and wife who made the behind-the-scenes work look effortless—the type of mom who’d greet the kids after school with a snack and listening ear, the kind of wife who insisted on one last Cancun vacation the week before dying of breast cancer at age 46.

“Obviously, she was the greatest—the greatest wife, mother, daughter, sister and friend,” says Greg, emotion in his voice. “Her favorite role in life was that of mom to Jake, Abby and Emme. These three were her everything, and she was their everything.” At times, that meant protecting the kids from the darker moments she experienced with cancer. “She did a very good job of separating what she was going through and making others feel comfortable. She tried to protect everybody.”

Even though Cindy avoided the spotlight, preferring to deal with her cancer privately while quietly counseling others who received similar diagnoses, Greg is certain of one thing: She would be incredibly proud of the fundraising the family has carried on in her name. And given the stellar treatment she received from The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) for nearly a decade until her passing in June 2016, without a doubt she would be pleased that the family’s fundraising continues to benefit breast cancer research at the OSUCCC – James.

“This community comes together”

The family’s fundraising efforts began in 2008, just a year after Cindy’s diagnosis. “Cindy never wanted to be a face of breast cancer,” says Greg. “As a breast cancer husband, there’s not much you can do but be there for your spouse. It was a release for me to do something.”

Drawing on both Greg and Cindy’s longtime roots in the Worthington community, they raised philanthropic dollars for the OSUCCC – James while having fun with a wide network of family and friends. “This is about the Worthington community. This community comes together when there’s tragedy or someone is sick,” says Greg, who often takes calls

Cindy Smullen

The Smullen family on vacation on Marco Island, Fla., in 2015.
from neighbors or acquaintances seeking advice on how to support a spouse with cancer. “People are apologetic, saying, ‘Sorry to be bringing this up.’ I say, ‘No, don’t be sorry.’ I love being able to be there for others who are going through this.”

And be there for others, the Smullens will. Following Cindy’s death, the family created their own endowment fund with the OSUCCC – James using the proceeds from the fundraisers they continue to hold each year. With endowments, the principal of the gift is invested and only the interest is spent, enabling support to continue in perpetuity. The Smullen Family Fund for Breast Cancer Research recently crossed the $50,000 mark to reach full funding, meaning it will begin to generate continuous income—a lasting reminder of the woman who inspired a family to become philanthropists.

**Rivals Rally Around a Cause**

The Smullen children, having seen the impact philanthropy can have firsthand, are getting into the act as well. During Jake’s senior year of high school, he and a date raised approximately $3,000 for breast cancer research through a winter formal competition at school; now a busy junior studying finance and business analytics at Ohio University, he plans to take up the mantle of fundraising to honor his mother’s journey after graduation.

Abby, a recent graduate of Worthington Kilbourne High School and now a first-year student at Miami University, created a lacrosse fundraiser this past year with rival Thomas Worthington High School. She coordinated with her athletic director and coach, as well as Thomas Worthington’s lacrosse team captain, Julia Geiger, to pull off a first-ever girls’ lacrosse rival game for charity. When all was said and done, Abby, her teammates, classmates and friends—as well as enthusiastic supporters from Thomas Worthington—raised $4,500 for the Smullen Family Fund for Breast Cancer Research by selling shirts specially designed for the game.

“It was really cool to see Thomas girls, who had no idea who I was, selling shirts,” says Abby. “It’s easy to get the girls who know and respect you, who knew your mom, to help. But I didn’t know many of the girls at Thomas.”

Her proud father concurs. “As much as they are rivals on the field and in social media, when something happens they come together. Both teams warmed up together wearing the shirts, and it was probably the most attended game I’ve seen in four years. The stands were full.”

The plans are for the rivalry game for charity to become an annual tradition. With younger sister Emme, a student at McCord Middle School, also playing lacrosse, there is a good chance the Smullens will continue this connection for years to come.

**Keeping Cindy’s Memory Alive**

Greg is quick to point out that the Smullen Family Fund for Breast Cancer Research is only at the beginning of what he hopes it can accomplish. With his children’s continued involvement and desire to see it flourish, and with the fund’s increasing recognition as a charity worthy of support in Worthington, there is no limit to the impact the Smullen family can have.

Though the hope is that the fund will impact many lives through breast cancer research breakthroughs, the family’s resolve remains personal. “My goal is to not let people forget Cindy,” says Greg. “If we keep the fund going, we keep her memory going.”
Donor Spotlight

More than 170 donors and friends gathered at Smith & Wollensky Restaurant in Easton Town Center on May 12 for the 17th annual Celebration for Life dinner to benefit The James Fund for Life, an annual fund at Ohio State that is chaired by Abigail and Les Wexner and raises money to buy leading-edge technology for studying and treating cancer.

This year’s event generated $1,232,986, bringing the total dollars raised for The James Fund for Life to $18.9 million since the fund was established in 2002. Funds from this year’s event will support the purchases of a new prone biopsy table, an automated breast ultrasound (ABUS) system and two mammography units for new satellite locations.

OSUCCC Director Raphael Pollock, MD, PhD, and James Interim CEO William Farrar, MD, extended their deep gratitude to the Easton Community Foundation and to Smith & Wollensky for their generous support over the years.

Left: Event chairs Judy and Steve Tuckerman announce the total dollars raised for The James Fund for Life since the fund’s establishment.

Shown from left at the 17th annual Celebration for Life dinner are OSUCCC Director Raphael Pollock, MD, Kathryn Farrar, James Interim CEO William Farrar, MD, and event chairs Judy and Steve Tuckerman.

‘Celebration for Life’
Raises $1.23 Million
To: Dr. Blakaj

We are so extremely grateful for all the staff at The James. Feb. 10, 2016, is the date kidney cancer was diagnosed. It has forever changed our lives, as have all of you. We are so thankful that we have had your guidance, care, wisdom, expertise, humor, availability and support all this time. We will continue to fight on and battle, and we know we are in the best care. We pray for all of you and will continue to pray for cures and miracles. We have hope!

From: The P. Family

To: Dr. Benson

As I approach my 10-year diagnosis anniversary, I am so thankful (as always!) for you and the fabulous team at The James. It’s been an interesting and sometimes challenging ride, but I keep hope alive thanks to you and my God. Bless you as you continue to reach for a cure. Love you!

From: Teresa P.

To: Dr. Carrau and Dr. Prevedello

Two years ago, you treated and saved my mom of a brain tumor in her olfactory nerve. After two complicated surgeries, radiation and a stay in the hospital because of the radiation side effects, she emerged from it all very weak and sad—as to be expected from a 78-year-old battling her third cancer. But last Dec. 24, we celebrated her 80th birthday! She is such a beautiful gift to our family, and I can’t thank you enough for the tender loving care you showed her and our family during this battle. I thank you for speaking to us in “normal” language that we could always understand. I thank you for looking us in the eye when you talked to us and showing you really care. Thank you for your years of diligent practice that allowed you the skills/abilities to perform the surgery through her nose—amazing! Most of all, thank you for being professional and caring at the same time.

From: Julie B.
An Unknown Illness, an Uncertain Future, an Unbreakable Spirit: A Journey Through Young Adult Cancer

Erica Mantell was entering her senior year at Ohio State when she confronted growing discomfort. “I started noticing these pains on my bones that felt like bruises that weren’t visible,” she says. “So I would call them my invisible bruises.”

Before long, those “invisible bruises” became agonizing pain. Soon, the cross-country runner accustomed to racing opponents was locked in a battle with her own body. “I couldn’t run anymore.”

Eventually the pain affected every area of Erica’s life, hindering her ability to walk, attend class or even get out of bed. While answers were absent, the pain was ever-present, resulting in multiple trips to emergency rooms and prescriptions that did little to ease her symptoms.

Despite Erica’s suspicion that cancer was the culprit—her father had died of the disease when she was 7—she hoped that her ailment was less serious, as it had yet to be identified.

Erica was referred to an oncologist at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), where testing confirmed acute lymphoblastic leukemia. “I was terrified, but I was so relieved,” she recalls. “I had some direction for the first time.”

Her new team at the OSUCCC – James wasted no time, starting chemotherapy the day after her diagnosis. Erica’s mom, refusing to leave her bedside, delivered a simple response: “We’re going to do this.”

For the 22-year-old athlete who just months before was preparing for final exams and medical school interviews, the physical manifestation of her treatment was jarring. Among the hurdles the illness placed in Erica’s path were a blood clot that caused seizures and forced her temporary admission to the ICU and a battle with depression that tested her mental resilience.
With every obstacle, though, came an opportunity to overcome, culminating in Erica’s discharge from the hospital and her graduation from Ohio State. She received the honor of leading the line of her college’s graduates. “I did it. I graduated. Bald, big steroid cheeks and everything—but I did it.”

From that moment, Erica took on the role of cancer survivor, working every day to regain her strength. After a bone marrow transplant, she started walking with regularity. By the next month, she was running again.

The support of friends and family served as the foundation for Erica’s recovery efforts, a fact that she stresses to young cancer patients who may not recognize the need for turning over some control of their lives.

“There has to be a process of understanding that you’re not going to be quite independent anymore,” she says. “It’s OK to ask for help. You’ve just been diagnosed with cancer.”

Erica’s support system includes friends, family members, doctors and nurses, along with her mom and her now-husband, Andrew. Together, he and Erica are navigating a post-cancer “new normal” that includes the aftermath of early menopause—and its impact on fertility—brought on by her treatment.

“[Andrew has been] amazingly understanding about everything,” Erica says. “I don’t feel any guilt, any shame for what has happened, but it’s still something that impacts us together.”

Despite her busy schedule, she finds time to advise young adult cancer patients and work with donors and supporters to encourage vital research funding. “It’s a community that I’ve entered with a whole bunch of compassionate and generous people. It’s amazing what people do to support cancer research.”

“Knowing how much research is done here allowed me to trust them completely,” Erica says of the OSUCCC – James. “I was only able to do that because I knew they were going to take care of me the best.”

A medical student at Ohio State, Erica is looking forward to a bright future while accepting that her past will always be a part of her present. “Cancer doesn’t define me, but it is part of my identity.”

Facing Cancer Under Age 40

About 70,000 young people (age 15-39) are diagnosed with cancer each year in the United States, according to the National Cancer Institute.

Adolescent and young adult (AYA) patients have their own unique diagnoses, complications, morbidities and psychosocial concerns. “It’s much harder on younger people because they’re going through major life transitions already,” says Maryam Lustberg, MD, MPH, medical director of survivorship at the OSUCCC – James. “There’s a huge need to have support tailored to their unique situation.”

Thanks to support from donors and events such as the Columbus Mac and Cheese Festival, research teams at Ohio State are studying the effects of cancer on young adults and building programs to help them navigate life through treatment—and beyond.

The 2018 Columbus Mac and Cheese Festival will take place Friday, Oct. 5 at Easton Town Center. Visit cbusmacandcheese.org for tickets and event information.
Top Pelotonia-Funded Areas of Impact

Ibrutinib is the first drug designed to target Bruton’s tyrosine kinase, a protein essential for chronic lymphocytic leukemia (CLL) cell survival and growth. In 2014, the U.S. Food and Drug Administration approved ibrutinib for relapsed CLL patients, making the drug available to thousands of cancer patients nationwide. Pelotonia-supported clinical and basic research led to the approval of this drug.

Beating Lung Cancer in Ohio (BLC-IO) is a statewide clinical research project funded by Pelotonia. The study aims to evaluate the impact of advanced gene testing and expert advice on lung cancer treatment and patient survival, improve smoking-cessation rates of lung cancer patients and their families and improve each patient’s quality of life. Annually, more people die of lung cancer than colon, breast and prostate cancers combined; this Pelotonia-funded study is designed to help change that.

The Ohio Colorectal Cancer Prevention Initiative (OCCPI) included 50 hospitals across Ohio to screen newly diagnosed colorectal cancer patients and their biological relatives for Lynch syndrome, an inherited cancer-causing condition. Individuals with Lynch syndrome are very likely to develop colorectal, uterine, ovarian or other cancers. This screening effort, funded by Pelotonia dollars, could save an estimated 1,000 years of life and provide some $32 million in benefit to the community because of lives saved in Ohio.

Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) is a statewide initiative to help identify women with endometrial (uterine) cancer who may be at risk for other types of cancer due to their genetic makeup, and to help match women with endometrial cancer to the best treatment options for their particular cancer. Pelotonia funding will make it possible for some 700 women from 25 partner hospitals in communities throughout Ohio to participate in this important prevention and treatment initiative.

Digital Pathology takes diseased tissue mounted on glass slides, scans the slides bit by bit and digitally knits the individual pictures together to make one highly detailed image. This virtual image is paired with clinical information to quickly give pathologists an integrated picture of each patient’s unique cancer so optimum therapy can be delivered sooner. Pelotonia dollars are helping to create a digital archive of past pathology specimens and associated clinical data to be made available to cancer investigators anywhere in the world.
At The James

The Oncology Research Information Exchange Network (ORIEN) is a national collaboration involving 18 cancer centers across the United States that are using a protocol called Total Cancer Care® (TCC) to hasten the development and delivery of more precise cancer treatments, diagnostic tools and prevention strategies through secure research-sharing of consented patient data. Pelotonia funds have enabled the OSUCCC – James to extend its reach by helping to establish ORIEN.

New Clinical Trials supported by Pelotonia dollars are finding better ways to prevent, detect and treat individual cancers. Trials in breast cancer, sarcoma, prostate cancer, thyroid cancer, leukemia and other forms of the disease are bringing hope to patients everywhere. To date, hundreds of patients have been enrolled in these Pelotonia-funded clinical trials, moving cancer research closer to our ultimate goal of a cancer-free world.

The Drug Development Institute was created to facilitate the development of promising laboratory discoveries into new cancer treatments. Taking a scientific discovery from the lab through product development, manufacturing, clinical trials and finally FDA approval is a daunting task. Thanks to support from Pelotonia and others, Ohio State’s Drug Development Institute has a team of experts dedicated to accelerating innovative research to speed cures to patients.

The Pelotonia Fellowship Program provides promising undergraduate, graduate, medical and postdoctoral students with grants to conduct cancer research in the labs of faculty mentors at Ohio State. Students in any discipline may apply for these prestigious grants. Pelotonia dollars have funded 476 fellowships since 2010, ensuring that the best and brightest minds remain in cancer research.

Physician-Scientists Supported by Pelotonia Dollars are bringing the best cancer research to Ohio State. The OSUCCC – James attracts some of the brightest minds in the field, and Pelotonia dollars help these scientists continue their research when they arrive. These researchers and the talented staff in their labs are discovering genetic abnormalities or triggers that lead to cancer, developing better prevention methods, more precisely targeting tumors based on their molecular profile and, most of all, bringing more hope to cancer patients everywhere.
OSUCCC – James Leaders Extol Cancer Program’s Caring Culture

OSUCCC – James leaders emphasized their commitment to continuing a culture of collaborative cancer care when addressing the audience at a May 2 community forum at the Fawcett Center. The “Meet the Cancer Program Leaders” forum gave the public a chance to become acquainted with Raphael Pollock, MD, PhD, director of the OSUCCC; William Farrar, MD, interim chief executive officer of The James; Peter Shields, MD, deputy director of the OSUCCC; and David Cohn, MD, chief medical officer of The James.

Following a reception, each physician spoke about himself, his career and why he enjoys working at Ohio State in a leadership role. A moderator then posed questions to the panelists, who were unanimous in their praise for a cancer program that has achieved great success stemming from a caring culture that has thrived here from the start.

Pollock said the OSUCCC – James has a strong reputation for its exceptional environment of collaborative, research-based clinical care. “Patients and staff essentially are looking for two qualities: authenticity and empathy,” he said. “The ability to provide both in the context of an outstanding collaborative environment such as we have is highly unusual.”

Providing historical context, Farrar said the OSUCCC – James’ integrated program of research and clinical care started in 1990 when the original cancer hospital opened. He noted that, as director of medical affairs at that time, he was privileged to “get in on the ground floor” and help develop a culture that has existed here “since day one.”

Shields and Cohn echoed the thoughts of Pollock and Farrar about the importance of a collaborative and caring culture but also went further. Shields noted that people are willing to support the program “because we’re producing good results,” and Cohn pointed out that physicians here think every day about research, providing “a remarkable opportunity to move the field forward.”

To view the leadership forum in its entirety, visit the OSUCCC – James YouTube channel.
A single upfront genomic test is more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than the traditional multiple sequential testing approach, according to new clinical data reported by the OSUCCC – James.

Researchers say offering this type of advanced genetic testing at the time of diagnosis could help guide and expedite treatment decisions for many patients who have CRC while simultaneously identifying patients who also are likely to have Lynch syndrome, a genetic condition that predisposes to colorectal and other types of cancer, including uterine, ovarian and stomach.

For this study, researchers wanted to know if an upfront tumor-sequencing approach using a single test that screens for multiple mutations could replace the current multiple-test screening approach commonly used to determine if a patient has Lynch syndrome.

To do this, researchers analyzed tumor samples from 419 CRC patients who participated in the Ohio Colorectal Cancer Prevention Initiative (OCCPI), a statewide research study to screen newly diagnosed CRC patients and their biological relatives for Lynch syndrome.

All OCCPI study participants had their tumor samples analyzed using the traditional multiple-test genetic testing approach and the single upfront genomic tumor-sequencing test approach in which a single tumor sample was analyzed for multiple mutations simultaneously.

Researchers compared results from the two screening methods and found that the upfront tumor-sequencing approach was more sensitive and more specific for detecting Lynch syndrome than the old, multiple-test model. Tumor sequencing resulted in a 10 percent improvement in Lynch syndrome detection rates while also providing important information about treatment options for the patients.

Study findings were reported in the March 29 issue of the medical journal JAMA Oncology. Heather Hampel, MS, LGC, associate director for biospecimen research and member of the Molecular Biology and Cancer Genetics Program at the OSUCCC – James, was corresponding author of the study and is the principal investigator of OCCPI.

OCCPI is funded by Pelotonia, a grassroots cycling event that has raised more than $173 million for cancer research at Ohio State.

“I think this test is really the future for treating not just colon and uterine cancers, but probably all cancers.”
— Heather Hampel
‘Floating Buckeye Nation’ Sets Sail and New Fundraising Record

When the Buckeye Cruise for Cancer returned from its 11th voyage last February, organizers at Travel Partners in Dublin and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) were elated.

Thanks to the generosity of the ship’s enthusiastic passengers, the cruise raised $3 million—exceeding the previous $2.5 million record set the year before. The annual fundraiser primarily benefits the Urban and Shelley Meyer Fund for Cancer Research and supports other cancer research funds at the OSUCCC – James. Says Travel Partners in Dublin President Lisa Cisco, who founded the Buckeye Cruise, “Somehow the cruise just keeps getting stronger. It’s hard to believe, because each year has been so special, but Buckeye Cruisers never stop amazing us and just keep setting the bar higher and higher.”

The ship has been dubbed the “floating Buckeye Nation,” with more than 2,300 Buckeyes from around the country descending on Fort Lauderdale, Fla., to board Royal Caribbean’s Serenade of the Seas. The Buckeye faithful were joined by more than 30 former Ohio State football greats, including A.J. Hawk, James Laurinaitis and Ezekiel Elliott, as well as current and former members of the Ohio State football coaching staff, such as Kerry Coombs, Stan Jefferson, Larry Johnson and Mark Pantoni. Together, players and fans soaked up some poolside sun, enjoyed dueling pianos under the stars and other Buckeye-themed entertainment, and stopped by places such as Labadee, Haiti, Royal Caribbean’s private island, and Key West, Fla., for some on-shore fun.

Through it all, the reason they are gathered is never far from the cruisers’ minds. “Go Bucks, Beat Cancer!” is commonly heard during the cruise, which includes a recognition of the more than 300 cancer survivors aboard the ship and presentations from several physicians whose work has benefited from funds raised by previous cruises.

There is no shortage of opportunities for inspiration to support cancer research. From an exciting live auction to a survivor breakfast, from a race/walk that more than 700 cruisers participated in during a stop at Key West to a celebrity horse race that raised more than $70,000 for the OSUCCC – James, participants had ample opportunity to give generously while having a great time.

“Cancer is such a terrible enemy,” says Stephen Chaykowski, assistant vice president for development at the OSUCCC – James. “I’m proud to see Buckeyes coming together during the cruise to say, ‘We’re going to beat cancer, and we’re going to do it together through our traditions and the strong relationships we’ve created.’”

Planning is already underway for next year’s cruise, which will set sail for CocoCay, Bahamas and Grand Cayman. Joining the cruise for the first time will be former Ohio State football assistant coach and NCAA coaching legend Lou Holtz, J.T. Barrett, Billy Price, Raekwon McMillan, Rex Kern and more! Visit buckeyecruise.com for more information about the Feb. 23-28, 2019, cruise and to book your cabin.

The pool deck is packed for an exciting game of “Heads or Tails,” another creative fundraiser on board the Buckeye Cruise.
CRUISERS SUPPORT “FUND A NEED” FOR CUTTING-EDGE TECHNOLOGY

Fund a Need, one of the fundraising highlights on the Buckeye Cruise for Cancer, enables cruisers to chip in to purchase important shared research equipment and technologies for the more than 340 researchers at the OSUCCC – James. Says Sara Cole, PhD, associate director of the Campus Microscopy and Imaging Facility, “One of the amazing things about the Buckeye Cruise for Cancer is they can help fund state-of-the-art instruments that we couldn’t get through other avenues.”

This year’s Fund a Need raised $400,000 to purchase a Thermo Scientific TSQ Altis Triple-Stage Quadrupole Mass Spectrometer. This technology offers researchers—most notably those who focus on detecting and treating cancer cells—unparalleled ability to analyze the most complex molecules and to detect cancer at its earliest stage. This robust scientific tool will enable the world-renowned cancer experts at the OSUCCC – James to improve cancer diagnosis, prognosis and treatment.
Community Partners

The OSUCCC – James Community Partners Program consists of corporations, individuals and community groups that raise funds in support of our vision to create a cancer-free world. From corporate initiatives to local events, our more than 400 Community Partners bring in significant dollars to further research, education and patient care. To learn more, please contact The James Development Office at 614-293-2120, communitypartnersevents@osumc.edu, or visit go.osu.edu/JamesCommunityPartners.

**Raise a Racket**

MORE THAN $40,000 RAISED

Benefiting the Diane Crawford Fund for Cervical Cancer Research, Education and Outreach ($10,000) and creating The Crawford Family Research Endowment Fund to End Cervical Cancer ($30,000)

www.thecrawfordcrew.org

Tennis balls whirled through the air on Jan. 20 at the sixth annual Raise a Racket, where more than 60 supporters of The Crawford Crew Foundation played tennis with the pros. The tennis pros hosted clinics before playing single and double matches for the spectators. Attendees then joined more than 400 additional guests at Villa Milano Banquet and Conference Center for an evening of food from local restaurants, live music, a silent auction and raffles.

**Burgundy Ball**

MORE THAN $125,000 RAISED

Benefiting the Multiple Myeloma Research Fund

Myeloma Crowd held its inaugural Burgundy Ball – Mission for a Cure in Myeloma, honoring Multiple Myeloma Opportunities for Research and Education (MMORE). The Feb. 3 event, emceed by Jackie Comisar, welcomed nearly 300 guests to L Brands, where they enjoyed an evening of dinner, dancing and fundraising to support the OSUCCC – James’ myeloma research projects and the Crowdcare Foundation’s Myeloma Crowd Research Initiative.

The gala included remarks from Myeloma Crowd founder Jenny Ahlstrom, patient David Schroeder and OSUCCC – James myeloma physicians Don Benson, MD, PhD, and Yvonne Efebera, MD. A Beacon Award was presented to MMORE founder Nancy Kaufmann.
The Head for the Cure 5K made its central Ohio debut at Genoa Park on April 15. The race—a celebration of hope for brain cancer patients, survivors and their families and friends—was a partnership with the Head for the Cure Foundation, based in Kansas City, Mo.

More than 300 participants rallied with teams in matching T-shirts. Vinay Puduvalli, MD, director of the Division of Neuro-Oncology at Ohio State, spoke about the importance of raising awareness and funds for brain cancer research.

Nominated by their loved ones, three individuals who are brain cancer survivors were honored at a Keeping the Faith ceremony. This special part of the event brought meaning to why the Head for the Cure 5K is so important: keeping the faith and continuing to fight! The race plans to return to Columbus in spring 2019.

The 18th annual Angel Open Golf Outing was held at Oakhaven Golf Club on June 8. The sold-out tournament, with both a morning and afternoon field of golfers, celebrated a major milestone this year—raising more than half a million dollars since the tournament began in 2001.

The 2018 proceeds will benefit colon cancer prevention initiatives led by Darrell Gray, MD, MPH, and brain cancer research conducted by Vinay Puduvalli, MD. Gray and Puduvalli addressed attendees between golf rounds, thanking them for their support and sharing more about the projects that donors are funding through their involvement in the Angel Open.
PULLL allows users to unlock and generate funds for cancer research through exercise (cycling, running, walking), all year round.

FOR MORE INFORMATION, VISIT PULLL.ORG

IT’S EASY! IT’S FREE! Download and use PULLL. Let’s change the world.
Steps for Sarcoma
Sept. 23, 2018
8:30 a.m. – noon
Chemical Abstracts Service
Columbus, Ohio
stepsforsarcomaevent.com
Proceeds benefit the Steps for Sarcoma Research Fund
The ninth annual Steps for Sarcoma is proud to be part of the James 5K Race Series. Please join us at the family- and pet-friendly race for a day of fun. The event includes walkers and runners, team photos, silent auction items, speaking program, music, face painting and more! This event continues to grow every year in participants and fundraising for sarcoma research. Last year, we had 1,300 registered participants and 150 dogs, and we raised $125,000! We now have an amazing six-year profit totaling more than $850,000.

10th Anniversary St. Marys Tailgate for Cancer
Oct. 13, 2018
Gates open at 1 p.m.
Fraternal Order of Eagles 767
St. Marys, Ohio
www.tailgateforcancer.com
Proceeds benefit the Urban and Shelley Meyer Fund for Cancer Research
Be at the best tailgate party in the state! Come join the great folks of St. Marys as they tailgate to end cancer and watch the Buckeyes beat Minnesota on the big screen! This two-day event features multiple live bands, auctions, raffles, a 5K and Ohio State alumni cheerleaders.

Columbus Donut Run
Oct. 28, 2018
9 a.m.
Genoa Park
Columbus, Ohio
joansfoundation.org/donutrun
Proceeds benefit the Joan Bisesi Fund for Head and Neck Oncology Research
The Columbus Donut Run is an annual 5K run/walk to benefit the Joan’s Foundation for Head and Neck Cancer Research. All participants will receive a limited edition Columbus Donut Run T-shirt and a half-dozen donuts. Participants can enjoy donut holes at every mile, and donuts and Starbucks coffee at the finish line.
Joan Levy Bisesi developed head and neck cancer at the age of 29. The fund was created before she passed away in 2001 with the mission to improve lives by raising funds to support head and neck cancer research, education, awareness and survivorship.

To see all community events that benefit the OSUCCC – James, please visit go.osu.edu/JamesCommunityPartners.

The James Cancer-Free World Podcast
• Features top OSUCCC – James physicians and researchers
• Topics include cutting-edge cancer research at Ohio State
• New episodes on the 2nd and 4th Tuesday of each month
cancer.osu.edu/podcast
COLUMBUS MAC & CHEESE Festival

FRIDAY, OCTOBER 5
EASTON TOWN CENTER

cbusmacandcheese.org

hosted by
benefiting the
adolescent & young adult cancer program

The James